PARADIGM BIOPHARMACEUTICAL LIMIT ORD
Paradigm’s iPPS shown to reduce cartilage loss and improve function in osteoarthritis patients
Late-stage drug development company Paradigm Biopharmaceuticals (ASX: PAR) has announced positive study data from a Phase 2 clinical trial of injectable pentosan polysulfate sodium (iPPS) for the treatment of acute pain associated with knee osteoarthritis. The study investigated changes in synovial fluid biomarkers with iPPS treatment compared with placebo in 61 participants administered with twice-weekly […]
Paradigm Biopharma’s knee osteoarthritis trial meets secondary endpoints, launches capital raise
Paradigm Biopharmaceuticals (ASX: PAR) has announced trial patients being treated with its injectable pentosan polysulfate sodium (iPPS) drug for osteoarthritis of the knee have confirmed improved knee function and pain reduction for six months. The biotechnology company today confirmed its phase 2b clinical trial has successfully met its key secondary endpoints of improved knee function […]
Paradigm Biopharmaceuticals advances Zilosul osteoarthritis program, to trial drug in MPS patients
Paradigm Biopharmaceuticals (ASX: PAR) has completed treatment of its Zilosul injectable pentosan polysulfate (iPPS) drug under the US Food and Drug Administration’s expanded access program, while collaring FDA orphan status for using it in treating MPS-I. Also known as compassionate use, the expanded access program provides a pathway for doctors to use investigational drugs, biologics […]
Paradigm doses all trial patients with Zilosul while dodging COVID-19 impact
An experimental treatment for knee osteoarthritis developed by Paradigm Biopharmaceuticals (ASX: PAR), Zilosul, has now been dosed in all ten patients under the FDA approved expanded access – otherwise known as compassionate use – program in the US. In a statement to investors, Paradigm said patients being treated are at different stages of the treatment […]
